PureIMS is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops®. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical needs. The company’s management team consists of seasoned life sciences executives who bring long-lasting and complementary experience in leading drug development, addressing applicable scientific issues and pursuing commercial and business development & licensing opportunities. PureIMS’s lead candidates – Colistin Cyclops® for pulmonary Pseudomonas aeruginosa infections and Levodopa Cyclops® as rescue therapy for OFF episodes in Parkinson’s disease – qualify for abbreviated regulatory routes. Moreover, Colistin Cyclops® is already marketed and reimbursed as a magistral or extemporaneously produced product in the Netherlands for cystic fibrosis (CF), non-CF bronchiectasis (NCFB) patients whom were not able to use authorized alternatives (e.g. due to a high treatment burden and consequentially low adherence or tolerability issues). This proves the superior tolerability and convenience of use compared to competitor products. To date, over 100k doses of Colistin Cyclops® have been prescribed this way. Other clinical programs – including Epinephrine Cyclops® for (food) allergy and impending anaphylaxis – are being explored in an early clinical stage. PureIMS also supports pharma/biotech partners, applying the Cyclops®-based inhalation route for their drug of choice.